Overview

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the efficacy of Eslicarbazepine acetate (ESL) as therapy in subjects with Post-herpetic Neuralgia (PHN) over a 15 week treatment phase.
Phase:
Phase 3
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Eslicarbazepine acetate